Alyeska Investment Group, L.P. Unicycive Therapeutics, Inc. Transaction History
Alyeska Investment Group, L.P.
- $25 Billion
- Q4 2024
A detailed history of Alyeska Investment Group, L.P. transactions in Unicycive Therapeutics, Inc. stock. As of the latest transaction made, Alyeska Investment Group, L.P. holds 1,750,000 shares of UNCY stock, worth $997,499. This represents 0.01% of its overall portfolio holdings.
Number of Shares
1,750,000
Previous 2,250,000
22.22%
Holding current value
$997,499
Previous $922,000
49.89%
% of portfolio
0.01%
Previous 0.01%
Shares
2 transactions
Others Institutions Holding UNCY
# of Institutions
32Shares Held
61.7MCall Options Held
0Put Options Held
0-
Great Point Partners LLC Greenwich, CT11MShares$6.26 Million5.72% of portfolio
-
Nantahala Capital Management, LLC New Canaan, CT10.4MShares$5.92 Million0.41% of portfolio
-
Octagon Capital Advisors LP New York, NY10MShares$5.7 Million1.76% of portfolio
-
Vivo Capital, LLC Palo Alto, CA9.97MShares$5.68 Million1.54% of portfolio
-
Logos Global Management LP San Francisco, CA5.08MShares$2.89 Million0.53% of portfolio
About Unicycive Therapeutics, Inc.
- Ticker UNCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 15,052,500
- Market Cap $8.58M
- Description
- Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Al...